share_log

藥明康德:翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

香港交易所 ·  Mar 19 05:15
Summary by Moomoo AI
無錫藥明康德新藥開發股份有限公司於2024年3月11日至19日進行了一系列股份回購活動,共回購2,797,126股A股股份。該公司於上海證券交易所進行的回購活動,並未註銷所購回的股份。根據香港聯合交易所有限公司證券上市規則,公司需披露已發行股本變動。回購股份的價格範圍在RMB 51.07至RMB 57.32之間,而回購的總金額達到RMB 20,095,471.8。公司董事李革確認,所有回購活動均已獲得董事會的正式授權批准,並符合相關法律規定。
無錫藥明康德新藥開發股份有限公司於2024年3月11日至19日進行了一系列股份回購活動,共回購2,797,126股A股股份。該公司於上海證券交易所進行的回購活動,並未註銷所購回的股份。根據香港聯合交易所有限公司證券上市規則,公司需披露已發行股本變動。回購股份的價格範圍在RMB 51.07至RMB 57.32之間,而回購的總金額達到RMB 20,095,471.8。公司董事李革確認,所有回購活動均已獲得董事會的正式授權批准,並符合相關法律規定。
WUXI PHARMACEUTICAL MING KAND NEW DRUG DEVELOPMENT CO., LTD. CONDUCTED A SERIES OF SHARE REPURCHASE ACTIVITIES FROM MARCH 11 TO 19, 2024, WITH A TOTAL OF 2,797,126 SHARES OF A SHARES. The repurchase activities carried out by the company on the Shanghai Stock Exchange did not write off the repurchased shares. Under the Listing Rules of the Hong Kong Stock Exchange Limited, companies are required to disclose changes in issued share capital. The price of the repurchased shares ranged from RMB 51.07 to RMB 57.32, while the total amount of the repurchases reached RMB 20,095,471.8. Director Li Gem confirmed that all repurchase activities have been formally authorized by the Board of Directors and comply with the relevant legal requirements.
WUXI PHARMACEUTICAL MING KAND NEW DRUG DEVELOPMENT CO., LTD. CONDUCTED A SERIES OF SHARE REPURCHASE ACTIVITIES FROM MARCH 11 TO 19, 2024, WITH A TOTAL OF 2,797,126 SHARES OF A SHARES. The repurchase activities carried out by the company on the Shanghai Stock Exchange did not write off the repurchased shares. Under the Listing Rules of the Hong Kong Stock Exchange Limited, companies are required to disclose changes in issued share capital. The price of the repurchased shares ranged from RMB 51.07 to RMB 57.32, while the total amount of the repurchases reached RMB 20,095,471.8. Director Li Gem confirmed that all repurchase activities have been formally authorized by the Board of Directors and comply with the relevant legal requirements.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more